{"title": "Liquid biopsy", "page_id": 45031863, "revision_id": 1219768203, "revision_timestamp": "2024-04-19T18:20:38Z", "content": "{{Short description|Sampling and analysis of non-solid biological tissues}}\n{{Infobox diagnostic\n| name            = Liquid biopsy\n| image           =\n| alt             =\n| caption         =\n| pronounce       =\n| purpose         =analysis of non-solid biological tissue\n| test of         =\n| based on        =\n| synonyms        = Fluid biopsy\n| reference_range =\n| calculator      =\n| DiseasesDB      = <!--{{DiseasesDB2|numeric_id}}-->\n| ICD10           = <!--{{ICD10|Group|Major|minor|LinkGroup|LinkMajor}} or {{ICD10PCS|code|char1/char2/char3/char4}}-->\n| ICD9            =\n| ICDO            =\n| MedlinePlus     = <!--article_number-->\n| eMedicine       = <!--article_number-->\n| MeshID          =\n| OPS301          = <!--{{OPS301|code}}-->\n| LOINC           = <!--{{LOINC|code}}-->\n}}\nA '''liquid biopsy''', also known as '''fluid biopsy''' or '''fluid phase biopsy''', is the sampling and analysis of non-solid biological tissue, primarily [[blood]].<ref>{{Cite journal|last1=Alix-Panabi\u00e8res|first1=Catherine|last2=Pantel|first2=Klaus|date=January 2013|title=Circulating tumor cells: liquid biopsy of cancer|journal=Clinical Chemistry|volume=59|issue=1|pages=110\u2013118|doi=10.1373/clinchem.2012.194258|issn=1530-8561|pmid=23014601|doi-access=free}}</ref><ref>{{cite journal|last1=Crowley|first1=Emily|last2=Di Nicolantonio|first2=Federica|last3=Loupakis|first3=Fotios|author4-link=Alberto Bardelli|last4=Bardelli|first4=Alberto|title=Liquid biopsy: monitoring cancer-genetics in the blood|journal=Nature Reviews Clinical Oncology|date=9 July 2013|volume=10|issue=8|pages=472\u2013484|doi=10.1038/nrclinonc.2013.110|pmid=23836314|s2cid=25537784}}</ref> Like traditional [[biopsy]], this type of technique is mainly used as a diagnostic and monitoring tool for diseases such as [[cancer]], with the added benefit of being largely non-invasive. Liquid biopsies may also be used to validate the efficiency of a cancer treatment drug by taking multiple samples in the span of a few weeks. The technology may also prove beneficial for patients after treatment to monitor [[relapse]].<ref>{{Cite news|url=https://www.economist.com/news/technology-quarterly/21728778-and-early-diagnosis-saves-lives-understanding-cancers-unruly-origins-helps-early-0|title=Understanding cancer's unruly origins helps early diagnosis |date=September 14, 2017 |newspaper=The Economist|access-date=2017-09-29}}</ref>\n\nThe clinical implementation of liquid biopsies is not yet widespread but is becoming [[standard of care]] in some areas.<ref>{{cite journal|last1=Gingras|first1=Isabelle|last2=Salgado|first2=Roberto|last3=Ignatiadis|first3=Michail|date=November 2015|title=Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?|journal=Current Opinion in Oncology|volume=27|issue=6|pages=560\u2013567|doi=10.1097/CCO.0000000000000223|pmid=26335664|s2cid=13339984}}</ref>\n\nLiquid biopsy refers to the molecular analysis in biological fluids of nucleic acids, subcellular structures, especially exosomes, and, in the context of cancer, circulating tumor cells.<ref>{{Cite web |title=Liquid Biopsy - an overview {{!}} ScienceDirect Topics |url=https://www.sciencedirect.com/topics/medicine-and-dentistry/liquid-biopsy |access-date=2023-11-08 |website=www.sciencedirect.com}}</ref>\n\n== Types ==\nThere are several types of liquid biopsy methods; method selection depends on the condition that is being studied.\n\n{| class=\"wikitable sortable\" border=\"1\"\n|-\n! scope=\"col\" | Disease\n! scope=\"col\" | Tissue sampled\n! scope=\"col\" | Sampling procedure\n! scope=\"col\" | Invasiveness\n! scope=\"col\" | Substance isolated\n! scope=\"col\" | Isolation and detection method\n! scope=\"col\" | Analysis\n! scope=\"col\" | Refs\n|-\n|Cancer (various) || Blood || [[Phlebotomy]] || Minimally invasive || [[Circulating tumor cell]]s (CTCs) || Various (e.g. [[CellSearch]], RosetteStep, [[Dynabeads]]) || Flow cytometry, nucleic acid extraction, immunocytochemistry, functional assays || <ref>{{cite journal |last1=Peeters |first1=D J E |last2=De Laere |first2=B |last3=Van den Eynden |first3=G G |last4=Van Laere |first4=S J |last5=Roth\u00e9 |first5=F |last6=Ignatiadis |first6=M |last7=Sieuwerts |first7=A M |last8=Lambrechts |first8=D |last9=Rutten |first9=A |last10=van Dam |first10=P A |last11=Pauwels |first11=P |last12=Peeters |first12=M |last13=Vermeulen |first13=P B |last14=Dirix |first14=L Y |title=Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting |journal=British Journal of Cancer |date=April 2013 |volume=108 |issue=6 |pages=1358\u20131367 |doi=10.1038/bjc.2013.92|pmid=23470469 |pmc=3619252 }}</ref><ref>{{cite journal |last1=Agerb\u00e6k |first1=Mette \u00d8. |last2=Bang-Christensen |first2=Sara R. |last3=Yang |first3=Ming-Hsin |last4=Clausen |first4=Thomas M. |last5=Pereira |first5=Marina A. |last6=Sharma |first6=Shreya |last7=Ditlev |first7=Sisse B. |last8=Nielsen |first8=Morten A. |last9=Choudhary |first9=Swati |last10=Gustavsson |first10=Tobias |last11=Sorensen |first11=Poul H. |last12=Meyer |first12=Tim |last13=Propper |first13=David |last14=Shamash |first14=Jonathan |last15=Theander |first15=Thor G. |last16=Aicher |first16=Alexandra |last17=Daugaard |first17=Mads |last18=Heeschen |first18=Christopher |last19=Salanti |first19=Ali |title=The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner |journal=Nature Communications |date=December 2018 |volume=9 |issue=1 |pages=3279 |doi=10.1038/s41467-018-05793-2|pmid=30115931 |pmc=6095877 |bibcode=2018NatCo...9.3279A }}</ref><ref>{{cite book |last1=Thiele |first1=Jana- A. |last2=Pitule |first2=Pavel |last3=Hicks |first3=James |last4=Kuhn |first4=Peter |title=Tumor Profiling |chapter=Single-Cell Analysis of Circulating Tumor Cells |series=Methods in Molecular Biology |date=2019 |volume=1908 |pages=243\u2013264 |doi=10.1007/978-1-4939-9004-7_17|pmid=30649733 |pmc=7679177 |isbn=978-1-4939-9002-3 }}</ref><ref>{{Cite journal |last=Nakazawa |first=M. |last2=Lu |first2=C. |last3=Chen |first3=Y. |last4=Paller |first4=C. J. |last5=Carducci |first5=M. A. |last6=Eisenberger |first6=M. A. |last7=Luo |first7=J. |last8=Antonarakis |first8=E. S. |date=2015-09-01 |title=Serial blood-based analysis of AR-V7 in men with advanced prostate cancer |url= |journal=Annals of Oncology |volume=26 |issue=9 |pages=1859\u20131865 |doi=10.1093/annonc/mdv282 |issn=0923-7534|pmc=4551160 }}</ref>\n|-\n|Cancer (various) || Blood || Phlebotomy || Minimally invasive || [[Circulating tumor DNA]] (ctDNA) || [[DNA extraction]] || [[Next-generation sequencing]] || <ref>{{cite journal|last1=Heitzer|first1=E.|last2=Ulz|first2=P.|last3=Geigl|first3=J. B.|title=Circulating Tumor DNA as a Liquid Biopsy for Cancer|journal=Clinical Chemistry|date=11 November 2014|volume=61|issue=1|pages=112\u2013123|doi=10.1373/clinchem.2014.222679|pmid=25388429|doi-access=free}}</ref><ref>{{cite journal|last1=Wan|first1=Jonathan C. M.|last2=Massie|first2=Charles|last3=Garcia-Corbacho|first3=Javier|last4=Mouliere|first4=Florent|last5=Brenton|first5=James D.|last6=Caldas|first6=Carlos|last7=Pacey|first7=Simon|last8=Baird|first8=Richard|last9=Rosenfeld|first9=Nitzan|title=Liquid biopsies come of age: towards implementation of circulating tumour DNA|journal=Nature Reviews Cancer|volume=17|issue=4|pages=223\u2013238|date=24 February 2017|doi=10.1038/nrc.2017.7|pmid=28233803|s2cid=4561229|url=https://www.repository.cam.ac.uk/handle/1810/262102}}</ref><ref name=\"pmid33310847\">{{cite journal | vauthors = Avanzini S, Kurtz DM, Chabon JJ, Moding EJ, Hori SS, Gambhir SS, Alizadeh AA, Diehn M, Reiter JG | title = A mathematical model of ctDNA shedding predicts tumor detection size | journal = Science Advances | volume = 6 | issue = 50 | pages = eabc4308 | date = December 2020 | pmid = 33310847 | doi = 10.1126/sciadv.abc4308 | pmc = 7732186 | bibcode = 2020SciA....6.4308A | s2cid = 228096858 | doi-access = free }}</ref>\n|-\n|[[Urothelial carcinoma]] || Urine || Urine collection || Non-invasive || Urinary tumor DNA (utDNA) || DNA extraction || Next-generation sequencing || <ref>{{cite journal |last1=Chaudhuri |first1=Aadel A. |last2=Pellini |first2=Bruna |last3=Pejovic |first3=Nadja |last4=Chauhan |first4=Pradeep S. |last5=Harris |first5=Peter K. |last6=Szymanski |first6=Jeffrey J. |last7=Smith |first7=Zachary L. |last8=Arora |first8=Vivek K. |title=Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management |journal=JCO Precision Oncology |date=November 2020 |volume=4 |issue=4 |pages=806\u2013817 |doi=10.1200/PO.20.00060|pmid=32923907 |pmc=7448529 }}</ref><ref>{{Cite journal |last1=Bicocca |first1=Vincent T. |last2=Phillips |first2=Kevin G. |last3=Fischer |first3=Daniel S. |last4=Caruso |first4=Vincent M. |last5=Goudarzi |first5=Mahdi |last6=Garcia-Ransom |first6=Monica |last7=Lentz |first7=Peter S. |last8=MacBride |first8=Andrew R. |last9=Jensen |first9=Brad W. |last10=Mazzarella |first10=Brian C. |last11=Koppie |first11=Theresa |last12=Korkola |first12=James E. |last13=Gray |first13=Joe W. |last14=Levin |first14=Trevor G. |date= September 2022 |title=Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention |journal=Journal of Clinical Medicine |language=en |volume=11 |issue=19 |pages=5827 |doi=10.3390/jcm11195827 |pmid=36233691 |pmc=9571552 |issn=2077-0383|doi-access=free }}</ref>\n|-\n|Non-urological cancers || Urine || Urine collection || Non-invasive || Urine proteins, metabolites || [[HPLC]]-[[Mass spectrometry|MS]] || [[Proteomics]], [[metabolomics]] || <ref>{{cite journal |last1=Ward |first1=DG |last2=Nyangoma |first2=S |last3=Joy |first3=H |last4=Hamilton |first4=E |last5=Wei |first5=W |last6=Tselepis |first6=C |last7=Steven |first7=N |last8=Wakelam |first8=MJ |last9=Johnson |first9=PJ |last10=Ismail |first10=T |last11=Martin |first11=A |title=Proteomic profiling of urine for the detection of colon cancer. |journal=Proteome Science |date=16 June 2008 |volume=6 |pages=19 |doi=10.1186/1477-5956-6-19 |pmid=18558005|pmc=2440369 |doi-access=free }}</ref><ref>{{cite journal |last1=Arasaradnam |first1=RP |last2=Wicaksono |first2=A |last3=O'Brien |first3=H |last4=Kocher |first4=HM |last5=Covington |first5=JA |last6=Crnogorac-Jurcevic |first6=T |title=Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine. |journal=Gastroenterology |date=February 2018 |volume=154 |issue=3 |pages=485\u2013487.e1 |doi=10.1053/j.gastro.2017.09.054 |pmid=29129714|doi-access=free }}</ref>\n|-\n|Bladder and prostate cancer\n|Urine\n|Urine collection\n|Non-invasive\n|Exfoliated cancer cells\n|[[Urinalysis]]\n|[[Fluorescence in situ hybridization]]\n|<ref>{{Cite journal |last=Halling |first=Kevin C. |last2=Kipp |first2=Benjamin R. |date=September 2008 |title=Bladder Cancer Detection Using FISH (UroVysion Assay) |url=https://journals.lww.com/00125480-200809000-00003 |journal=Advances in Anatomic Pathology |language=en |volume=15 |issue=5 |pages=279\u2013286 |doi=10.1097/PAP.0b013e3181832320 |issn=1072-4109}}</ref><ref>{{Cite journal |last=Eskra |first=Jillian N. |last2=Rabizadeh |first2=Daniel |last3=Mangold |first3=Leslie |last4=Fabian |first4=Elizabeth |last5=Brennen |first5=W. Nathaniel |last6=Yeater |first6=David B. |last7=Pienta |first7=Kenneth J. |last8=Partin |first8=Alan W. |last9=Isaacs |first9=William B. |last10=Pavlovich |first10=Christian P. |last11=Luo |first11=Jun |date=2020-08-20 |title=A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization |url=https://www.nature.com/articles/s41391-020-00272-6 |journal=Prostate Cancer and Prostatic Diseases |language=en |volume=24 |issue=1 |pages=220\u2013232 |doi=10.1038/s41391-020-00272-6 |issn=1365-7852}}</ref>\n|-\n|[[Heart attack]] || Blood || Phlebotomy || Minimally invasive || [[Circulating endothelial cell]]s (CECs) || Various (e.g. CellSearch, HD-CEC)|| Flow cytometry || <ref>{{cite journal |last1=Bethel |first1=Kelly |last2=Luttgen |first2=Madelyn S |last3=Damani |first3=Samir |last4=Kolatkar |first4=Anand |last5=Lamy |first5=Rachelle |last6=Sabouri-Ghomi |first6=Mohsen |last7=Topol |first7=Sarah |last8=Topol |first8=Eric J |last9=Kuhn |first9=Peter |title=Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction |journal=Physical Biology |date=9 January 2014 |volume=11 |issue=1 |pages=016002 |doi=10.1088/1478-3975/11/1/016002|pmid=24406475 |pmc=4143170 |bibcode=2014PhBio..11a6002B }}</ref>\n|-\n|Neurological diseases || [[Cerebrospinal fluid]] || [[Lumbar puncture]] || Invasive || CSF proteins, nucleic acids || Various|| [[ELISA]], [[Multiplex (assay)|multiplex assay]], next-generation sequencing || <ref>{{cite journal|last1=Pyykk\u00f6|first1=Okko T.|last2=Lumela|first2=Miikka|last3=Rummukainen|first3=Jaana|last4=Nerg|first4=Ossi|last5=Sepp\u00e4l\u00e4|first5=Toni T.|last6=Herukka|first6=Sanna-Kaisa|last7=Koivisto|first7=Anne M.|last8=Alafuzoff|first8=Irina|last9=Puli|first9=Lakshman|last10=Savolainen|first10=Sakari|last11=Soininen|first11=Hilkka|last12=J\u00e4\u00e4skel\u00e4inen|first12=Juha E.|last13=Hiltunen|first13=Mikko|last14=Zetterberg|first14=Henrik|last15=Leinonen|first15=Ville|last16=Fiandaca|first16=Massimo S.|title=Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus|journal=PLOS ONE|date=17 March 2014|volume=9|issue=3|pages=e91974|doi=10.1371/journal.pone.0091974|pmid=24638077|pmc=3956805|bibcode=2014PLoSO...991974P|doi-access=free}}</ref><ref>{{cite journal | pmc=6284385 | pmid=30401727 | doi=10.15252/emmm.201809323 | volume=10 | issue=12 | pages=e9323 | title=Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients | year=2018 | author=Mouliere F, Mair R, Chandrananda D, Marass F, Smith CG, Su J, Morris J, Watts C, Brindle KM, Rosenfeld N | journal=EMBO Mol Med}}</ref>\n|-\n|[[Prenatal diagnosis]] || Blood (maternal) || Phlebotomy || Minimally invasive || [[Cell-free fetal DNA]] (cffDNA) || DNA extraction || [[Karyotyping]], [[fluorescent in situ hybridization]] || <ref>{{cite journal |last1=Rafi |first1=Imran |last2=Hill |first2=Melissa |last3=Hayward |first3=Judith |last4=Chitty |first4=Lyn S |title=Non-invasive prenatal testing: use of cell-free fetal DNA in Down syndrome screening |journal=British Journal of General Practice |date=July 2017 |volume=67 |issue=660 |pages=298\u2013299 |doi=10.3399/bjgp17X691625|pmid=28663415 |pmc=5565870 }}</ref>\n|-\n|Prenatal diagnosis || Blood (maternal) || Phlebotomy || Minimally invasive || Fetal cells in maternal blood (FCMB) || Flow cytometry || Karyotyping, fluorescent in situ hybridization || <ref>{{cite journal |last1=Singh |first1=Ripudaman |last2=Hatt |first2=Lotte |last3=Ravn |first3=Katarina |last4=Vogel |first4=Ida |last5=Petersen |first5=Olav Bj\u00f8rn |last6=Uldbjerg |first6=Niels |last7=Schelde |first7=Palle |title=Fetal cells in maternal blood for prenatal diagnosis: a love story rekindled |journal=Biomarkers in Medicine |date=September 2017 |volume=11 |issue=9 |pages=705\u2013710 |doi=10.2217/bmm-2017-0055|pmid=28617034 |doi-access=free }}</ref>\n|-\n|Prenatal diagnosis || Blood ([[umbilical cord]]) || [[Percutaneous umbilical cord blood sampling|Cordocentesis]] || Invasive || Umbilical blood cells and molecules || Various || Karyotyping, [[blood typing]], [[blood test]]s, [[Kleihauer\u2013Betke test]], flow cytometry || <ref>{{cite book |last1=Weiner |first1=Carl P. |last2=Lee |first2=Gene T. |editor-first1=Joseph J. |editor-first2=Anthony M. |editor-first3=Vincenzo |editor-first4=Jesus R. |editor-last1=Apuzzio |editor-last2=Vintzileos |editor-last3=Berghella |editor-last4=Alvarez-Perez |title=Operative Obstetrics, 4E |date=2017 |publisher=Routledge |isbn=978-1-4987-2056-4 |url=https://www.taylorfrancis.com/chapters/edit/10.1201/9781315382739-16/cordocentesis-carl-weiner-gene-lee |chapter=Cordocentesis|doi=10.1201/9781315382739 }}</ref>\n|-\n|Prenatal diagnosis || [[Amniotic fluid]] || [[Amniocentesis]] || Invasive || Amniotic fluid cells and molecules || Various || Karyotyping, blood typing, [[lecithin\u2013sphingomyelin ratio|L/S ratio]], [[Surfactant\u2013albumin ratio|S/A ratio]] || <ref>{{cite book |last1= Perni |first1=Sriram C. |last2=Roost |first2=John R. |last3=Chervenak| first3=Frank A. |editor-first1=Joseph J. |editor-first2=Anthony M. |editor-first3=Vincenzo |editor-first4=Jesus R. |editor-last1=Apuzzio |editor-last2=Vintzileos |editor-last3=Berghella |editor-last4=Alvarez-Perez |title=Operative Obstetrics, 4E |date=2017 |publisher=Routledge |isbn=978-1-4987-2056-4 |url=https://www.taylorfrancis.com/chapters/edit/10.1201/9781315382739-11/amniocentesis-sriram-perni-john-roost-frank-chervenak |chapter=Amniocentesis|doi=10.1201/9781315382739 }}</ref>\n|-\n|}\n\nA wide variety of [[biomarker]]s may be studied to detect or monitor other diseases. For example, isolation of [[protoporphyrin IX]] from blood samples can be used as a diagnostic tool for [[atherosclerosis]].<ref>{{cite journal|last1=Nascimento da Silva|first1=Monica|last2=Sicchieri|first2=Let\u00edcia Bonfante|last3=Rodrigues de Oliveira Silva|first3=Fl\u00e1via|last4=Andrade|first4=Maira Franco|last5=Courrol|first5=Lilia Coronato|title=Liquid biopsy of atherosclerosis using protoporphyrin IX as a biomarker|journal=The Analyst|date=2014|volume=139|issue=6|pages=1383\u20138|doi=10.1039/c3an01945d|pmid=24432352|bibcode=2014Ana...139.1383N|s2cid=25707729 }}</ref> Cancer biomarkers in the blood include [[Prostate-specific antigen|PSA]] (prostate cancer), [[CA19-9]] (pancreatic cancer) and [[CA-125]] (ovarian cancer).\n\n== Mechanism ==\n{{Main|Circulating tumor cell#Detection methods|Circulating tumor DNA#Analysis of ctDNA}}\nCirculating tumor DNA (ctDNA) refers to DNA released by cancerous cells into the blood stream.<ref>{{Cite web|title=What is circulating tumor DNA and how is it used to diagnose and manage cancer?: MedlinePlus Genetics|url=https://medlineplus.gov/genetics/understanding/testing/circulatingtumordna/|access-date=2021-09-03|website=medlineplus.gov|language=en}}</ref><ref>[https://ghr.nlm.nih.gov/primer/testing/circulatingtumordna \"What is circulating tumor DNA and how is it used to diagnose and manage cancer? \"]. ''National Institutes of Health Genetics Home Reference''. 5 March 2019. Retrieved 12 March 2019.</ref> Cancer mutations in ctDNA mirror those found in traditional tumor biopsies, which allows them to be used as molecular biomarkers to track the disease.<ref>[http://oncpracticemanagement.com/issue-archive/2016/july-2016-vol-6-no-7/liquid-biopsies-show-high-correlation-with-tissue-biopsy-for-genetic-mutations/ \"Liquid Biopsies Show High Correlation with Tissue Biopsy for Genetic Mutations\"] {{Webarchive|url=https://web.archive.org/web/20221017061029/https://oncpracticemanagement.com/issue-archive/2016/july-2016-vol-6-no-7/liquid-biopsies-show-high-correlation-with-tissue-biopsy-for-genetic-mutations/ |date=2022-10-17 }}. ''Oncology Practice Management''. July 2016. Retrieved 12 March 2019.</ref><ref>[https://evcna.com/article/view/5081/ \"Cell-free DNA as a biomarker in cancer\"]. ''Extracell Vesicles Circ Nucleic Acid''. Aug 2022. Retrieved 04 Aug 2022.</ref>\nThese tests can have sensitive limits of detection, allowing monitoring of [[minimal residual disease]] after treatment. Scientists can purify and analyze ctDNA using [[massive parallel sequencing|next-generation sequencing]] (NGS) or PCR-based methods such as [[digital PCR]].<ref>Picher, Andy.[https://www.genengnews.com/insights/liquid-biopsy-key-for-precision-medicine/ \"Liquid Biopsy, Key for Precision Medicine\"]. ''Genetic Engineering & Biotechnology News''. 23 July 2018. Retrieved 12 March 2019.</ref> NGS-based methods provide a comprehensive view of a cancer\u2019s genetic makeup and is especially useful in diagnosis while digital PCR offers a more targeted approach especially well-suited for detecting minimal residual disease and for monitoring treatment response and disease progression.<ref>[https://www.onclive.com/insights/liquid-biopsy-nsclc/liquid-biopsy-differences-among-technologies \"Liquid Biopsy: Differences Among Technologies\"] {{Webarchive|url=https://web.archive.org/web/20171115045534/http://www.onclive.com/insights/liquid-biopsy-nsclc/liquid-biopsy-differences-among-technologies |date=2017-11-15 }}. ''OncLive''. 17 September 2017. Retrieved 12 March 2019.</ref><ref>Ellis, Jen.[https://www.biocompare.com/Editorial-Articles/349585-dPCR-The-Emergence-of-the-Digital-Age/ \"dPCR: The Emergence of the Digital Age\"]. ''Biocompare''. 7 May 2018. Retrieved 12 March 2019.</ref> Recent progress in epigenetics has expanded the use of liquid biopsy for the detection of early-stage cancers, including by approaches such as [[Cancer Likelihood in Plasma]] (CLiP) .<ref>{{cite journal | pmid=31614115 | doi=10.1016/j.ccell.2019.09.003 | volume=36 | issue=4 | pages=350\u2013368 | title=Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA | year=2019 | author=van der Pol Y, Mouliere F | journal=Cancer Cell| doi-access=free }}</ref>\n\nLiquid biopsies can detect changes in tumor burden months or years before conventional imaging tests can, making them suitable for early tumor detection, monitoring, and detection of resistance mutations.<ref>McDowell, Sandy.[https://www.cancer.org/latest-news/liquid-biopsies-past-present-future.html \"Liquid Biopsies: Past, Present, and Future\"]. ''American Cancer Society''. 12 February 2018. Retrieved 12 March 2019.</ref><ref>[https://www.cancer.gov/news-events/cancer-currents-blog/2017/liquid-biopsy-detects-treats-cancer \"Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer\"]. ''National Cancer Institute''. 8 November 2017. Retrieved 12 March 2019.</ref><ref>{{cite journal | last1 = Olsson | first1 = Eleonor | last2 = Winter | first2 = Christof | date = 2015 | title = Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease | journal = EMBO Molecular Medicine | volume = 7 | issue = 8 | pages = 1034\u20131047 | doi = 10.15252/emmm.201404913 | pmid = 25987569 | pmc = 4551342 }}</ref>  The increase in the adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine are expected to drive growth in the global liquid biopsy market.<ref>{{Cite web |title=Liquid Biopsy Market - A Global and Regional Analysis: Focus on Offering, Usage, Workflow, Circulating Biomarker, Sample, Technology, Clinical Application, End User, and Region - Analysis and Forecast, 2022-2032 |url=https://bisresearch.com/industry-report/liquid-biopsy-market-report.html |access-date=2022-09-19 |website=bisresearch.com |language=en}}</ref>\n\n== Clinical application ==\n\nIn [[cancer]], liquid biopsy can be used for either [[Cancer_screening#Multi-cancer_blood_tests|multi-cancer screening tests]],<ref>{{cite journal |last1=Brito-Rocha |first1=Tiago |last2=Const\u00e2ncio |first2=Vera |last3=Henrique |first3=Rui |last4=Jer\u00f3nimo |first4=Carmen |title=Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests |journal=Cells |date=18 March 2023 |volume=12 |issue=6 |pages=935 |doi=10.3390/cells12060935 |doi-access=free |pmid=36980276 |pmc=10047029 |issn=2073-4409}}</ref> when solid tumor biopsies are not possible, to compare different treatments as part of clinical trials, to inform decisions for doctors/patients on which [[precision medicine]] treatment to select, and for [[minimal residual disease]] detection (disease monitoring). Liquid biopsy of [[circulating tumor DNA]] for [[Epidermal growth factor receptor|EGFR]]-mutated [[lung cancer]] is approved by the FDA.<ref>{{Cite journal|last=Kwapisz|first=Dorota|date=February 2017|title=The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?|journal=Annals of Translational Medicine|volume=5|issue=3|page=46|doi=10.21037/atm.2017.01.32|issn=2305-5839|pmc=5326656|pmid=28251125 |doi-access=free }}</ref>\n\nThe [[CellSearch]] method for enumeration of [[circulating tumor cell]]s in metastatic breast, metastatic colon, and metastatic prostate cancer has been validated and approved by the [[FDA]] as a useful prognostic method.<ref name=\"NK\">{{cite journal|last1=Karachaliou|first1=N|last2=Mayo-de-Las-Casas|first2=C|last3=Molina-Vila|first3=MA|last4=Rosell|first4=R|date=March 2015|title=Real-time liquid biopsies become a reality in cancer treatment.|journal=Annals of Translational Medicine|volume=3|issue=3|pages=36|doi=10.3978/j.issn.2305-5839.2015.01.16|pmc=4356857|pmid=25815297}}</ref>\n\n== See also ==\n* [[Radiography|Radiographic imaging]]\n* [https://generegulation.org/nucposdb/ NucPosDB: a database of nucleosome positioning in vivo and nucleosomics of cell-free DNA]\n* [[Cancer screening#Blood tests]]\n* [[Circulating free DNA]]\n\n== References ==\n{{reflist}}\n\n[[Category:Biopsy]]\n[[Category:Medical procedures]]\n[[Category:Cancer screening]]"}